DEF: BioAtla Schedules 2026 Annual Meeting of Stockholders

Sentiment:

Proxy Statement 3 June 2026 4:07 PM

BioAtla, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 16, 2026, to be held virtually, with key proposals including director elections and executive compensation.

Delay expectedForms 4 were filed late on February 24, 2025, on behalf of Drs. Short and Sievers and Messrs. Vasquez and Waldron relating to shares withheld by the Company to satisfy income tax and withholding obligations in connection with the vesting and net settlement of previously reported restricted stock units, due to administrative error.

Summary

BioAtla, Inc. is holding its 2026 Annual Meeting of Stockholders on Thursday, July 16, 2026, at 8:00 a.m. Pacific Time.
The meeting will be conducted virtually via live webcast, with no physical location.
Stockholders of record as of May 18, 2026, are eligible to vote.
Key proposals include the election of two Class III directors, ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation.
Proxy materials will be available online, and stockholders are encouraged to vote by internet, telephone, or mail.
The company has undergone a 50-for-1 share consolidation effective April 6, 2026, with all historical share and per-share amounts adjusted accordingly.
The board of directors recommends voting FOR all proposals.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine proxy statement focused on corporate governance and shareholder voting, rather than significant financial or operational updates.

Positives

The company is holding its annual meeting to engage with stockholders and address key governance matters.
The virtual format allows for broader participation regardless of physical location.
The company has a robust corporate governance structure with independent directors and committees.
All non-employee directors met their stock ownership requirements for fiscal year 2025.
The company has implemented a compensation clawback policy and prohibits hedging or pledging of its securities.

Negatives

No annual bonuses were paid to Named Executive Officers (NEOs) for 2025 due to the company not meeting the threshold corporate goal achievement.
Scott Smith will cease to serve as a director following the Annual Meeting.
There was a delay in filing Forms 4 for Drs. Short and Sievers and Messrs. Vasquez and Waldron due to administrative error.

Risks

The transaction with Inversagen AI LLC for the ozuriftamab vedotin (Oz-V) Phase 3 Study has not closed and is being re-evaluated due to recent events, including a strategic options exploration and workforce reduction.
The company does not have any products approved for sale and has not generated revenue from product sales.
The company's ability to recruit, incentivize, and retain talented individuals is critical in the competitive biotechnology market.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, it outlines the proposals to be voted on at the annual meeting, which will shape the company's governance and operational direction. The company is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumors, with ongoing Phase 2 and Phase 1 clinical trials.

Management Comments

"Your vote is important. Whether or not you expect to attend and participate in the Annual Meeting, please vote as soon as possible."
"We believe that our proprietary technology and approach have the potential to transform cancer therapy by decreasing systemic toxicities and improving efficacy."
"Our board of directors believes it is in our best interest to make that determination based on our position and direction and the membership of the board of directors."

Industry Context

StockSavvy.ai notes that BioAtla's proxy statement reflects standard corporate governance practices for a publicly traded biotechnology company, including the election of directors, auditor ratification, and advisory votes on executive compensation. The company's focus on developing novel antibody-based therapeutics for solid tumors aligns with significant trends in the oncology drug development sector.

Comparison to Industry Standards

The company's peer group for executive compensation includes 24 US-based, public pre-commercial biopharmaceutical companies in Phases 1-3 of clinical trials, with market capitalizations between $50 million and $500 million, and generally under 200 employees.
The compensation committee's use of an independent compensation consultant (Aon) is a common practice among industry peers.
The company's stock ownership guidelines for directors and executives, and its compensation clawback policy, are consistent with industry best practices.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Class III Director	Scott Smith	Edward Williams	July 16, 2026	Term expiration and non-nomination for re-election.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Leadership Structure	The board of directors has appointed Dr. Lawrence Steinman as Lead Independent Director, as Dr. Jay M. Short serves as both Chairman and CEO.	Ongoing	Ensures independent oversight and coordination of independent directors' activities.
Director Independence	The board has determined that all nominees and current members, except Dr. Short, are independent according to Nasdaq rules.	Ongoing	Strengthens corporate governance by ensuring a majority of independent directors and independent committee members.
Stock Ownership Guidelines	Non-employee directors are required to own stock valued at three times their annual cash retainer within five years.	Ongoing	Aligns directors' interests with those of stockholders.

Related Party Transactions

Clinical Trial Services Agreement with Himalaya Therapeutics SEZC (Himalaya) for services related to clinical trials in China.
Global Transaction Agreement with Himalaya, consenting to BioAtla's execution of the Context License Agreement and granting BioAtla a license for impacted products and intellectual property.
Investment Agreement with Inversagen AI LLC (Inversagen AI) for the sale of common units in a subsidiary (SPV) to advance ozuriftamab vedotin (Oz-V) in Phase 3 Study. This transaction is currently not closed and is being re-evaluated.

Stakeholder Impact

Stockholders: Will vote on director elections, auditor ratification, and executive compensation, influencing corporate governance and strategy.
Employees: The company's focus on attracting and retaining talent is highlighted, with equity incentives designed to align interests.
Management: Subject to advisory vote on compensation and subject to stock ownership guidelines and clawback policies.

Next Steps

Stockholders to vote on the proposed resolutions at the Annual Meeting.
Election of Class III directors for a three-year term.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
Advisory vote on the executive compensation of named executive officers.
The company will file a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to disclose voting results.

Key Dates

Date	Description
2026-05-18	Record Date for determining stockholders entitled to vote at the Annual Meeting.
2026-06-03	Date of the Proxy Statement and Notice of Annual Meeting.
2026-06-05	Expected mailing date of the Notice of Internet Availability of Proxy Materials.
2026-07-16	Date of the 2026 Annual Meeting of Stockholders.
2027-02-03	Deadline for stockholder proposals to be included in proxy materials for the 2027 Annual Meeting.
2027-03-18	Earliest date for stockholder proposals to be presented at the 2027 Annual Meeting.
2027-04-17	Latest date for stockholder proposals to be presented at the 2027 Annual Meeting.

Recommendation

hold

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic updates that would warrant a change in investment recommendation. The company's focus remains on clinical development, and the proposals are standard governance items. Investors should rely on other filings for performance-based decisions.

Keywords

BioAtla, DEF 14A, Proxy Statement, Annual Meeting, Stockholders, Director Election, Executive Compensation, Independent Auditor, Virtual Meeting, Share Consolidation, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.